You can buy or sell NBSE and other stocks, options, ETFs, and crypto commission-free!
NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington’s Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. Read More The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA. The listed name for NBSE is NeuBase Therapeutics, Inc. Common Stock.
52 Week High
52 Week Low
— per share
-$0.18 per share